Health Plans Have the SDoH Data. New Research Shows only 7% are Highly Effective at Using It.

Sage Growth Partners found that while 60% of surveyed health-plan leaders collect social drivers of health data, only 7% consider their organizations very effective at using it to improve maternal-health outcomes. Key gaps include rural OB/GYN access (66%), high-risk maternal specialist access (62%) and behavioral-health/postpartum-depression services (56%). Although 64% of leaders accept ROI timelines of up to three years for SDoH investments, the findings highlight operational shortcomings rather than an immediately investable catalyst.

Analysis

This is not a GEHC-specific earnings catalyst; it is a slow-moving procurement signal. The monetizable layer sits in workflow orchestration, care-management analytics and interoperability rather than diagnostic hardware, so any read-through to GEHC is indirect and likely immaterial over the next 1-3 quarters. Plans will demand evidence that data activation lowers costly preterm, NICU and postpartum behavioral-health utilization before expanding budgets, favoring vendors able to integrate claims, clinical and community-resource workflows rather than point-solution screening tools.

The likely 6-18 month competitive beneficiary is incumbent health-plan infrastructure: Elevance (ELV), CVS Health/Aetna (CVS), Centene (CNC), UnitedHealth/Optum (UNH) and Molina (MOH) can spread care-navigation investment across large Medicaid and managed-care populations. However, any savings accrue with a lag while implementation, staffing and community-network expense are immediate; Medicaid redetermination or enrollment volatility can also reduce the member base over which fixed platform costs are amortized. For GEHC, the relevant watch item is whether maternal/NICU providers begin attaching analytics and remote-monitoring spend to capital-equipment refreshes; absent disclosed order growth or software attach-rate improvement, this does not alter the fundamental thesis.

Consensus may overstate near-term value from social-data collection because the bottleneck is operational capacity, not data availability. The strongest signal would be payer disclosures linking targeted navigation programs to lower NICU days, fewer avoidable ED visits or improved prenatal-visit completion; without independently reported utilization savings, vendor ROI claims should be discounted. A deterioration in state Medicaid rates or higher medical-cost trends would make plans prioritize near-term utilization management over multi-year maternal-health pilots.

Key Decisions for Investors

• No standalone GEHC trade: maintain existing exposure only; upgrade the thesis only if quarterly disclosures show healthcare digital/AI software growth or maternal/NICU workflow wins accelerating beyond the core imaging cycle.
• Watch-list ELV and UNH for 6-18 month relative outperformance versus Medicaid-heavy CNC/MOH: scale into long ELV or UNH / short CNC only after evidence of stable Medicaid membership and medical-cost trends, since larger platforms can absorb care-management fixed costs more efficiently.
• Avoid treating this research as a near-term catalyst for maternal-health point solutions or hospital equipment suppliers; require independently disclosed reduction in NICU utilization or a named payer contract before underwriting revenue.
• Risk trigger for any payer-quality long: exit or hedge if medical-loss-ratio guidance rises materially on maternal/postpartum utilization, or if state Medicaid reimbursement updates fail to fund care-management investment; the near-term expense burden can precede savings by several quarters.